AR042536A1 - Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente - Google Patents
Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescenteInfo
- Publication number
- AR042536A1 AR042536A1 ARP030104716A ARP030104716A AR042536A1 AR 042536 A1 AR042536 A1 AR 042536A1 AR P030104716 A ARP030104716 A AR P030104716A AR P030104716 A ARP030104716 A AR P030104716A AR 042536 A1 AR042536 A1 AR 042536A1
- Authority
- AR
- Argentina
- Prior art keywords
- hygroscopic
- delicuescent
- pharmaco
- solid dispersions
- glycerides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Se proporciona una composición farmacéutica, que comprende un dispersión sólida que tiene un medio de vehículo que comprende (a) un agente formador de matriz seleccionado entre el grupo constituido por hidroixetilcelulosa, hidroxilpropilcelulosa, hidroxipropilmetilcelulosa, ftalato de hidroxipropilmetilcelulosa, polivinilpirrolidona, poplietilenglicol, glicéridos, poliglicolizados, ciclodextrinas y carbómeros, y (b) una carga, y teniendo un fármaco higroscópico y/o delicuescente nicotina o dispersado o disuelto en el medio de vehículo. La composición es aceptablemente no higroscópica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43542202P | 2002-12-19 | 2002-12-19 | |
US43514702P | 2002-12-19 | 2002-12-19 | |
US43502202P | 2002-12-19 | 2002-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042536A1 true AR042536A1 (es) | 2005-06-22 |
Family
ID=32719157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104684A AR042511A1 (es) | 2002-12-19 | 2003-12-17 | Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico |
ARP030104716A AR042536A1 (es) | 2002-12-19 | 2003-12-18 | Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104684A AR042511A1 (es) | 2002-12-19 | 2003-12-17 | Intermedio de formulacion no higroscopico que comprende un farmaco higroscopico |
Country Status (17)
Country | Link |
---|---|
US (2) | US20050013856A1 (es) |
EP (2) | EP1575563B1 (es) |
JP (2) | JP2006513238A (es) |
AR (2) | AR042511A1 (es) |
AT (1) | ATE353633T1 (es) |
AU (2) | AU2003298010A1 (es) |
BR (2) | BR0317392A (es) |
CA (2) | CA2511385A1 (es) |
DE (1) | DE60311875T2 (es) |
ES (1) | ES2280835T3 (es) |
HN (1) | HN2003000417A (es) |
MX (2) | MXPA05006802A (es) |
NL (1) | NL1025069C2 (es) |
PE (1) | PE20040972A1 (es) |
TW (2) | TW200423971A (es) |
UY (1) | UY28138A1 (es) |
WO (2) | WO2004060352A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
PT1243263E (pt) * | 2001-03-21 | 2003-03-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma |
SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
ATE353633T1 (de) * | 2002-12-19 | 2007-03-15 | Pharmacia Corp | Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält |
NO346973B1 (en) | 2002-12-20 | 2023-03-20 | Niconovum Ab | A physically and chemically stable nicotine-containing particulate material |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
FR2865133B1 (fr) * | 2004-01-19 | 2008-01-18 | Rytek | Compositions pour le traitement de pathologies digestives |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
EP1734980A1 (en) | 2004-04-16 | 2006-12-27 | Schwarz Pharma Ag | Use of peptidic compounds for the prophylaxis and treatment of chronic headache |
WO2006004480A1 (en) * | 2004-07-02 | 2006-01-12 | Radi Medical Systems Ab | Smokeless toabacco product |
CA2573125A1 (en) | 2004-08-27 | 2006-03-02 | Schwarz Pharma Ag | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain |
US20060147518A1 (en) * | 2004-12-30 | 2006-07-06 | Pierre Fabre Medicament | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
WO2007060540A1 (en) * | 2005-11-25 | 2007-05-31 | Aurobindo Pharma Limited | Stable dosage forms of an antidepressant |
US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
PT2029110E (pt) * | 2006-06-06 | 2011-11-23 | Tibotec Pharm Ltd | Processo para preparar formulações secas por atomização de tmc125 |
EA027836B1 (ru) | 2006-06-15 | 2017-09-29 | ЮСиБи ФАРМА ГМБХ | Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
ZA200905094B (en) * | 2006-12-22 | 2010-09-29 | Yuhan Corp | Revaprazan-containing solid dispersion and process for the preparation thereof |
JP2010538008A (ja) * | 2007-08-30 | 2010-12-09 | プレリーフ・インコーポレイテッド | 呼吸器系疾患または症状を処置および予防するためのグリセロリン酸カルシウム |
US9358242B2 (en) * | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
KR101499533B1 (ko) | 2008-02-15 | 2015-03-09 | 주식회사 씨티씨바이오 | 콜린 알포세레이트 함유 약학 제제 |
DE102008020701A1 (de) * | 2008-04-24 | 2009-10-29 | Bayer Technology Services Gmbh | Formulierung mit reduzierter Hygroskopizität |
DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
KR101172699B1 (ko) | 2011-05-16 | 2012-08-09 | 한국프라임제약주식회사 | 콜린알포세레이트를 함유하는 약학 제제, 및 그의 제조방법 |
US20140130759A1 (en) | 2011-07-07 | 2014-05-15 | The Lubrizol Corporation | Lubricant Providing Improved Cleanliness For Two-Stroke Cycle Engines |
CN102525992A (zh) * | 2012-03-09 | 2012-07-04 | 徐奎 | L-α-甘油磷酸胆碱薄膜衣片及其制备方法 |
ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
WO2013175505A1 (en) * | 2012-05-21 | 2013-11-28 | Hetero Research Foundation | Elvitegravir solid dispersion |
WO2017161387A1 (en) * | 2016-03-18 | 2017-09-21 | Reid Christopher Brian | Compositions of natural extracts and use thereof in methods for preventing or treating diseases |
CN113181110A (zh) | 2013-07-19 | 2021-07-30 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
EP3106150B1 (en) * | 2013-12-04 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Improved pharmaceutical compositions of pimobendan |
GB2525170A (en) * | 2014-04-07 | 2015-10-21 | Nokia Technologies Oy | Stereo viewing |
CN104739776A (zh) * | 2015-04-15 | 2015-07-01 | 福州乾正药业有限公司 | 左卡尼汀的固体分散体组合物及其制备方法和药物应用 |
WO2017013591A1 (en) * | 2015-07-22 | 2017-01-26 | Leiutis Pharmaceuticals Pvt Ltd | Stabilized liquid formulation of levothyroxine |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
CN111902422A (zh) * | 2018-03-30 | 2020-11-06 | 株式会社钟化 | 含有氧化型谷胱甘肽的固体组合物及其制造方法 |
CN112316678A (zh) * | 2020-10-12 | 2021-02-05 | 常州市永勃机械有限公司 | 一种变电站柜体用驱潮剂制备工艺制备方法 |
IT202100018578A1 (it) * | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4835187A (en) * | 1987-06-15 | 1989-05-30 | American Home Products Corporation | Spray dried ibuprofen |
JPH02218621A (ja) * | 1989-02-20 | 1990-08-31 | Nippon Chemiphar Co Ltd | 徐放性製剤 |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
SE9303574D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
EP0729748B1 (en) * | 1993-11-18 | 2003-02-26 | Nippon Shinyaku Company, Limited | Process for producing stable medicinal composition |
JPH08157392A (ja) * | 1994-12-01 | 1996-06-18 | Kanegafuchi Chem Ind Co Ltd | 放出制御型製剤 |
GB9607955D0 (en) * | 1996-04-17 | 1996-06-19 | Tillotts Pharma Ag | Hydrophobic carbomer salt compositions |
JPH10182448A (ja) * | 1996-12-24 | 1998-07-07 | Zensei Yakuhin Kogyo Kk | 圧縮製剤用組成物の製造方法 |
MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
JP4205340B2 (ja) * | 2000-03-24 | 2009-01-07 | ファルマシア コーポレーション | 酸化窒素シンターゼ阻害剤として有用なアミジノ化合物およびその塩 |
US20020143058A1 (en) * | 2001-01-24 | 2002-10-03 | Taro Pharmaceutical Inductries Ltd. | Process for preparing non-hygroscopic sodium valproate composition |
ATE353633T1 (de) * | 2002-12-19 | 2007-03-15 | Pharmacia Corp | Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält |
-
2003
- 2003-12-05 AT AT03796731T patent/ATE353633T1/de not_active IP Right Cessation
- 2003-12-05 EP EP03796731A patent/EP1575563B1/en not_active Expired - Lifetime
- 2003-12-05 WO PCT/US2003/038792 patent/WO2004060352A1/en active IP Right Grant
- 2003-12-05 CA CA002511385A patent/CA2511385A1/en not_active Abandoned
- 2003-12-05 DE DE60311875T patent/DE60311875T2/de not_active Expired - Fee Related
- 2003-12-05 ES ES03796731T patent/ES2280835T3/es not_active Expired - Lifetime
- 2003-12-05 AU AU2003298010A patent/AU2003298010A1/en not_active Abandoned
- 2003-12-05 MX MXPA05006802A patent/MXPA05006802A/es unknown
- 2003-12-05 BR BR0317392-5A patent/BR0317392A/pt not_active IP Right Cessation
- 2003-12-05 JP JP2004565235A patent/JP2006513238A/ja active Pending
- 2003-12-11 CA CA002509261A patent/CA2509261A1/en not_active Abandoned
- 2003-12-11 MX MXPA05005667A patent/MXPA05005667A/es unknown
- 2003-12-11 EP EP03814729A patent/EP1575564A1/en not_active Withdrawn
- 2003-12-11 WO PCT/US2003/039510 patent/WO2004060353A1/en not_active Application Discontinuation
- 2003-12-11 JP JP2004565403A patent/JP2006514052A/ja not_active Withdrawn
- 2003-12-11 BR BR0317103-5A patent/BR0317103A/pt not_active IP Right Cessation
- 2003-12-11 AU AU2003296948A patent/AU2003296948A1/en not_active Abandoned
- 2003-12-17 TW TW092135756A patent/TW200423971A/zh unknown
- 2003-12-17 AR ARP030104684A patent/AR042511A1/es unknown
- 2003-12-18 NL NL1025069A patent/NL1025069C2/nl not_active IP Right Cessation
- 2003-12-18 US US10/741,526 patent/US20050013856A1/en not_active Abandoned
- 2003-12-18 TW TW092135960A patent/TW200413006A/zh unknown
- 2003-12-18 AR ARP030104716A patent/AR042536A1/es unknown
- 2003-12-18 US US10/741,530 patent/US20040197411A1/en not_active Abandoned
- 2003-12-19 HN HN2003000417A patent/HN2003000417A/es unknown
- 2003-12-19 UY UY28138A patent/UY28138A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000027A patent/PE20040972A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR042511A1 (es) | 2005-06-22 |
EP1575564A1 (en) | 2005-09-21 |
MXPA05005667A (es) | 2005-07-26 |
AU2003298010A1 (en) | 2004-07-29 |
WO2004060353A9 (en) | 2004-10-07 |
CA2511385A1 (en) | 2004-07-22 |
WO2004060353A1 (en) | 2004-07-22 |
DE60311875D1 (de) | 2007-03-29 |
CA2509261A1 (en) | 2004-07-22 |
US20050013856A1 (en) | 2005-01-20 |
US20040197411A1 (en) | 2004-10-07 |
MXPA05006802A (es) | 2005-09-08 |
BR0317392A (pt) | 2005-12-20 |
NL1025069A1 (nl) | 2004-07-01 |
NL1025069C2 (nl) | 2005-02-16 |
HN2003000417A (es) | 2005-11-01 |
WO2004060352A8 (en) | 2005-09-15 |
EP1575563B1 (en) | 2007-02-14 |
WO2004060352A1 (en) | 2004-07-22 |
ATE353633T1 (de) | 2007-03-15 |
ES2280835T3 (es) | 2007-09-16 |
AU2003296948A1 (en) | 2004-07-29 |
DE60311875T2 (de) | 2007-08-30 |
JP2006514052A (ja) | 2006-04-27 |
EP1575563A1 (en) | 2005-09-21 |
JP2006513238A (ja) | 2006-04-20 |
PE20040972A1 (es) | 2004-12-14 |
BR0317103A (pt) | 2005-10-25 |
UY28138A1 (es) | 2004-08-31 |
TW200423971A (en) | 2004-11-16 |
TW200413006A (en) | 2004-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042536A1 (es) | Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente | |
GT200600474A (es) | Composiciones farmaceuticas solidas que contienen pregabalina | |
DE60205749D1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
BRPI0414000A (pt) | composição farmacêutica sólida, forma de dosagem, uso da composição farmacêutica, e, método para a preparação da composição | |
DK1183014T3 (da) | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse | |
UY30442A1 (es) | Composiciones farmaccuticas de ropinirol, mctodos de uso, proceso de preparacinn y aplicaciones. | |
BRPI0416613A (pt) | composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão | |
PA8578301A1 (es) | Composicion de tabletas de liberacion sostenida de pramipexol | |
SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
BR0316564A (pt) | Forma de dosagem de alérgeno | |
SE0102438D0 (sv) | New compounds | |
CY1105771T1 (el) | Φαρμακευτικες συνθεσεις εφαρμογης στον βλεννογονο | |
CY1105247T1 (el) | Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης | |
SE0004671D0 (sv) | Pharmaceutical formulation | |
EA200400148A1 (ru) | Стабилизированная суспензионная лекарственная форма для перорального применения | |
DE60134245D1 (de) | (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten | |
CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
BR0008228A (pt) | Composições de n-benzoil estaurosporinaespontaneamente dispersìveis | |
UY27929A1 (es) | Composiciones farmaceuticas de farmacos semiordenados y polimeros | |
IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
CO5690532A2 (es) | Formas de dosificacion farmaceutica de liberacion extendida | |
ATE357928T1 (de) | Pharmazeutische zusammensetzung für thrombinpeptidderivaten | |
TR200100895T2 (tr) | Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı | |
DE60102590D1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
DZ3473A1 (fr) | Formulation pharmaceutique a liberation prolongee independante de la force ionique. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |